Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring
epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer …

The development and clinical application of inhibitors that target the epidermal growth factor
receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …

Developing blood-based tests is appealing for non-invasive disease diagnosis, especially
when biopsy is difficult, costly, and sometimes not even an option. Tumor-derived exosomes …

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …

Abstract c-Abl is normally regulated by an autoinhibitory mechanism, the disruption of which
leads to chronic myelogenous leukemia. The details of this mechanism have been elusive …

Since in most tumors multiple signaling pathways are involved, many of the inhibitors in
clinical development are designed to affect a wide range of targeted kinases. The most …

The insulin-like growth factor-I (IGF-I) signaling induces epithelial to mesenchymal transition
(EMT) program and contributes to metastasis and drug resistance in several subtypes of …

Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been
found to be effective against lung cancer in vitro, but clinical resistance to these agents has …

Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-
tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an …

The impact of KRAS mutations on cetuximab sensitivity in epidermal growth factor receptor
fluorescence in situ hybridisation-positive (EGFR FISH+) metastatic colorectal cancer …